LLY vs. NVO
Compare and contrast key facts about Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: LLY or NVO.
Correlation
The correlation between LLY and NVO is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
LLY vs. NVO - Performance Comparison
Key characteristics
LLY:
0.52
NVO:
-0.70
LLY:
0.93
NVO:
-0.80
LLY:
1.12
NVO:
0.89
LLY:
0.67
NVO:
-0.55
LLY:
1.67
NVO:
-1.48
LLY:
9.68%
NVO:
17.13%
LLY:
31.10%
NVO:
36.27%
LLY:
-68.27%
NVO:
-71.31%
LLY:
-24.28%
NVO:
-46.24%
Fundamentals
LLY:
$652.65B
NVO:
$352.92B
LLY:
$9.29
NVO:
$2.93
LLY:
78.12
NVO:
26.86
LLY:
0.72
NVO:
1.28
LLY:
$31.51B
NVO:
$204.72B
LLY:
$25.63B
NVO:
$173.22B
LLY:
$9.48B
NVO:
$108.42B
Returns By Period
In the year-to-date period, LLY achieves a -5.99% return, which is significantly higher than NVO's -8.52% return. Over the past 10 years, LLY has outperformed NVO with an annualized return of 28.49%, while NVO has yielded a comparatively lower 15.98% annualized return.
LLY
-5.99%
-5.48%
-15.94%
16.21%
40.66%
28.49%
NVO
-8.52%
-7.42%
-40.69%
-25.62%
22.79%
15.98%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
LLY vs. NVO — Risk-Adjusted Performance Rank
LLY
NVO
LLY vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
LLY vs. NVO - Dividend Comparison
LLY's dividend yield for the trailing twelve months is around 0.72%, less than NVO's 1.83% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 0.72% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.95% | 2.46% | 2.77% | 2.37% | 2.84% |
NVO Novo Nordisk A/S | 1.83% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
Drawdowns
LLY vs. NVO - Drawdown Comparison
The maximum LLY drawdown since its inception was -68.27%, roughly equal to the maximum NVO drawdown of -71.31%. Use the drawdown chart below to compare losses from any high point for LLY and NVO. For additional features, visit the drawdowns tool.
Volatility
LLY vs. NVO - Volatility Comparison
The current volatility for Eli Lilly and Company (LLY) is 10.25%, while Novo Nordisk A/S (NVO) has a volatility of 21.75%. This indicates that LLY experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
LLY vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Eli Lilly and Company and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities